Teva (TEVA) EVP & CHRO Jover Placid Sells 12,827 Shares

What Happened

• Jover Placid, Executive Vice President and Chief Human Resources Officer at Teva (TEVA), had 12,827 restricted share units convert/vest and sold 12,827 shares in an open-market transaction on August 3, 2026. The weighted-average sale price was $34.88, generating proceeds of approximately $447,351.
• The transactions reflect conversion/exercise of derivative awards tied to RSUs and an immediate market sale of the vested shares (a routine sale of compensation-related shares, not a buy).

Key Details

• Transaction date: August 3, 2026; Form filed August 5, 2026 (timely).
• Sale: 12,827 shares disposed at a weighted-average price of $34.88; reported price range $34.66–$35.07.
• Source of shares: Restricted share units that vested/converted (derivative code M); reporting person sold vested shares, including shares to cover tax withholding obligations (footnote).
• Trade plan: Sale effected pursuant to a Rule 10b5-1 trading plan adopted November 10, 2025.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Additional notes: Each ordinary share may be represented by an American Depositary Share (ADS) (footnote). The filer offers to provide per-price breakouts on request (weighted average reported).

Context

• This was a compensation-related sale following RSU vesting (conversion then sale). Such transactions are common for executives when equity awards vest and often reflect portfolio liquidity/tax needs rather than a market view.
• The use of a 10b5-1 plan means the sales were pre-planned, which reduces — but does not eliminate — the amount of insight into the insider’s current sentiment.